“Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s98. doi:10.25251/skin.4.supp.98.